A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo

Global trends in esophageal cancer

(2017) Gautam K. Malhotra et al.   JOURNAL OF SURGICAL ONCOLOGY

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer

(2016) Toshi Takaoka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis

(2016) Simona R. Volovat et al.   JOURNAL OF CHEMOTHERAPY

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

(2016) Koichi Goto et al.   LANCET ONCOLOGY

The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression

(2016) Jiandong Chen   Cold Spring Harbor Perspectives in Medicine

The role of DNA damage responses in p53 biology

(2015) Daniel Speidel   ARCHIVES OF TOXICOLOGY

Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer

(2015) Kathryn Ottolino-Perry et al.   Molecular Oncology

Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan

(2015) Atlal Abu-Sanad et al.   Frontiers in Pharmacology

DNA replication stress: Causes, resolution and disease

(2014) Abdelghani Mazouzi et al.   EXPERIMENTAL CELL RESEARCH

Cancer survival in China, 2003-2005: A population-based study

(2014) Hongmei Zeng et al.   INTERNATIONAL JOURNAL OF CANCER

CFS-1686 Causes Cell Cycle Arrest at Intra-S Phase by Interference of Interaction of Topoisomerase 1 with DNA

(2014) Ru-Wei Lin et al.   PLoS One

Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump

(2013) T. Mazard et al.   MOLECULAR CANCER THERAPEUTICS

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo

(2012) Dharmendra Kumar Maurya et al.   JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy

(2011) Christiane Maria Rosina Thallinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer: A SEER Database Analysis

(2011) Attila Dubecz et al.   Journal of Thoracic Oncology

Phase I Trial of Weekly Topotecan and Gemcitabine in Patients With Solid Tumors

(2010) William N. William et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A Novel DNA Topoisomerase I Inhibitor with Different Mechanism from Camptothecin Induces G2/M Phase Cell Cycle Arrest to K562 Cells

(2010) Ning Wu et al.   BIOCHEMISTRY

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors

(2008) Giovanni Luca Beretta et al.   EXPERT OPINION ON THERAPEUTIC TARGETS